Department of Biotechnology, BIT-Campus, Anna University, Tiruchirappalli, Tamil Nadu, India.
Department of Biochemistry, Jagadguru Sri Shivarathreeshwara University, Mysuru, Karnataka, India.
Clin Rev Allergy Immunol. 2018 Jun;54(3):480-492. doi: 10.1007/s12016-016-8589-9.
Lack of markers of subclinical disease state and clinical phenotype other than pulmonary function test has made the diagnosis and interventions of environmental respiratory diseases a major challenge. MicroRNAs (miRNAs), small non-coding single stranded RNAs, have emerged as potential disease-modifier in various environmental respiratory diseases. They can also be found in various body fluids and are remarkably stable. Because of their high stability, disease-specific expression, and the ease to detect and quantify them have raised the potential of miRNAs in body fluids to be useful clinical diagnostic biomarkers for lung disease phenotyping. In the present review, we provide a comprehensive overview of progress made in identifying miRNAs in various body fluids including blood, serum, plasma, bronchoalveolar lavage (BAL) fluid, and sputum as biomarkers for a wide range of human respiratory diseases such as acute lung injury/acute respiratory distress syndrome (ALI/ARDS), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and asthma. Finally, we discuss several challenges remain to be concerned and suggest few disease-specific and non-specific miRNAs to become part of future clinical practice.
除肺功能测试外,缺乏亚临床疾病状态和临床表型标志物,使得环境呼吸道疾病的诊断和干预成为一个主要挑战。微小 RNA(miRNA)是一种小型非编码单链 RNA,已成为各种环境呼吸道疾病的潜在疾病修饰因子。它们也存在于各种体液中,并且非常稳定。由于其高稳定性、疾病特异性表达以及易于检测和定量,体液中的 miRNA 有可能成为肺病表型的有用临床诊断生物标志物。在本综述中,我们全面概述了在鉴定各种体液(包括血液、血清、血浆、支气管肺泡灌洗液和痰液)中的 miRNA 方面取得的进展,这些 miRNA 可作为广泛的人类呼吸疾病(如急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)、特发性肺纤维化(IPF)、慢性阻塞性肺疾病(COPD)和哮喘)的生物标志物。最后,我们讨论了仍需关注的几个挑战,并提出了一些疾病特异性和非特异性 miRNA,以成为未来临床实践的一部分。